Scarica l'app Stockscreener
2.71
5.57%
-0.16
Dopo l'orario di chiusura:
2.75
0.04
+1.48%
Precedente Chiudi:
$2.87
Aprire:
$2.76
Volume 24 ore:
1.31M
Relative Volume:
0.83
Capitalizzazione di mercato:
$267.94M
Reddito:
$58.36M
Utile/perdita netta:
$-25.72M
Rapporto P/E:
-7.443
EPS:
-0.3641
Flusso di cassa netto:
$-24.91M
1 W Prestazione:
-10.26%
1M Prestazione:
-0.73%
6M Prestazione:
-45.25%
1 anno Prestazione:
-34.86%
Intervallo 1D:
$2.615
$2.825
Intervallo di 1 settimana:
$2.615
$3.05
Portata 52W:
$2.24
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Nome
Aquestive Therapeutics Inc
Settore
Telefono
908-941-1900
Indirizzo
30 TECHNOLOGY DRIVE, WARREN, NJ
Confronta AQST con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
2.71 | 267.94M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
151.73 | 67.94B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.72 | 46.50B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.89 | 44.66B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.80 | 15.81B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
292.46 | 13.14B | 2.76B | 1.11B | 898.10M | 22.77 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-10 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Piper Sandler | Overweight |
| 2024-03-28 | Iniziato | Raymond James | Outperform |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2019-04-22 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-03 | Iniziato | Lake Street | Buy |
| 2018-08-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2018-08-20 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
New Jersey Pharma Co. Shares Positive Pediatric Study - streetwisereports.com
Aquestive completes marketing application for Anaphylm in U.S. - MSN
Aquestive stock gains as Anaphylm NDA completes (AQST:NASDAQ) - Seeking Alpha
Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data - Benzinga
Aquestive Therapeutics’ Anaphylm NDA Submission and Strong Clinical Profile Support Buy Rating - TipRanks
Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film - BioSpace
Aquestive Therapeutics Awaits FDA Decision on Anaphylm NDA - TipRanks
Aquestive’s Anaphylm shows promise in pediatric study - Investing.com
Aquestive Therapeutics Announces Positive Topline PK - GlobeNewswire
Revolutionary Allergy Treatment Proves Safe in Children: Game-Changing Alternative to EpiPen Heads to FDA - Stock Titan
Charles Schwab Investment Management Inc. Grows Stock Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World
Aquestive stock falls amid Libervant approval, Anaphylm update - MSN
Bank of New York Mellon Corp Reduces Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells Buy - Seeking Alpha
Aquestive Therapeutics: Not For Me, But Attractive (NASDAQ:AQST) - Seeking Alpha
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark - simplywall.st
What is HC Wainwright’s Estimate for AQST Q1 Earnings? - Defense World
What is HC Wainwright’s Forecast for AQST FY2026 Earnings? - Defense World
Aquestive Therapeutics (NASDAQ:AQST) Given Buy Rating at HC Wainwright - Defense World
Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Aquestive Therapeutics Advances Product Pipeline and Market Access - TipRanks
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Earnings Call Transcript - Insider Monkey
Buy Rating on Aquestive Therapeutics Driven by Anaphylm’s Regulatory Progress and Strategic Launch Preparations - TipRanks
Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings - MSN
Lake Street Capital Lowers Aquestive Therapeutics (NASDAQ:AQST) Price Target to $8.00 - Defense World
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts - Yahoo Finance
Aquestive Therapeutics price target lowered to $4.75 from $5.50 at Alliance Global Partners - TipRanks
New York State Common Retirement Fund Grows Stock Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Aquestive Therapeutics: Strategic Advancements and Financial Strength Underpin Buy Rating - TipRanks
Earnings call transcript: Aquestive Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com UK
Earnings call transcript: Aquestive Therapeutics Q4 2024 misses estimates - Investing.com
Aquestive Therapeutics: Q4 Earnings Snapshot - Midland Daily News
Aquestive Therapeutics (AQST) Reports Q4 Loss, Lags Revenue Estimates - MSN
Aquestive Therapeutics Q4 Net Loss Widens, Revenue Falls; 2025 Revenue Outlook Issued - Marketscreener.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Aquestive Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Compared to Estimates, Aquestive Therapeutics (AQST) Q4 Earnings: A Look at Key Metrics - Nasdaq
Aquestive Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aquestive Therapeutics reports Q4 EPS (19c), consensus (13c) - TipRanks
Aquestive Therapeutics misses Q4 estimates, shares fall By Investing.com - Investing.com South Africa
Aquestive Therapeutics misses Q4 estimates, shares fall - Investing.com India
Aquestive Therapeutics Inc Azioni (AQST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):